IRIS UniCatt

Voso, Maria Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.278
EU - Europa 5.163
AS - Asia 4.168
SA - Sud America 699
AF - Africa 103
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 7
Totale 16.438
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.157
DE - Germania 1.889
SG - Singapore 1.701
CN - Cina 1.408
SE - Svezia 734
PL - Polonia 585
BR - Brasile 576
UA - Ucraina 451
IT - Italia 389
FR - Francia 350
VN - Vietnam 326
GB - Regno Unito 200
IE - Irlanda 184
IN - India 151
FI - Finlandia 126
ID - Indonesia 110
RU - Federazione Russa 91
JP - Giappone 89
TR - Turchia 73
HK - Hong Kong 59
BD - Bangladesh 48
CA - Canada 47
IQ - Iraq 41
MX - Messico 40
AR - Argentina 36
NL - Olanda 36
PK - Pakistan 31
ZA - Sudafrica 29
CO - Colombia 24
BE - Belgio 19
CI - Costa d'Avorio 19
AU - Australia 17
ES - Italia 17
VE - Venezuela 16
AT - Austria 14
KR - Corea 14
EC - Ecuador 13
UZ - Uzbekistan 13
GR - Grecia 11
IR - Iran 11
MA - Marocco 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
JO - Giordania 10
CZ - Repubblica Ceca 9
IL - Israele 9
KE - Kenya 9
LT - Lituania 9
PY - Paraguay 9
SA - Arabia Saudita 9
EG - Egitto 8
PH - Filippine 8
TN - Tunisia 8
BG - Bulgaria 7
CH - Svizzera 7
CR - Costa Rica 7
PE - Perù 7
TH - Thailandia 7
JM - Giamaica 6
KZ - Kazakistan 6
DO - Repubblica Dominicana 5
ET - Etiopia 5
HN - Honduras 5
MY - Malesia 5
RO - Romania 5
BO - Bolivia 4
NO - Norvegia 4
SK - Slovacchia (Repubblica Slovacca) 4
AL - Albania 3
AM - Armenia 3
AZ - Azerbaigian 3
BH - Bahrain 3
DZ - Algeria 3
GE - Georgia 3
HR - Croazia 3
HU - Ungheria 3
NP - Nepal 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
SV - El Salvador 3
UY - Uruguay 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
BW - Botswana 2
DK - Danimarca 2
EU - Europa 2
GH - Ghana 2
LA - Repubblica Popolare Democratica del Laos 2
LB - Libano 2
LV - Lettonia 2
NI - Nicaragua 2
NZ - Nuova Zelanda 2
PS - Palestinian Territory 2
TT - Trinidad e Tobago 2
A1 - Anonimo 1
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BY - Bielorussia 1
FJ - Figi 1
Totale 16.422
Salva come PNG Salva come JPEG
Città #
Singapore 945
Chandler 735
Ashburn 638
Warsaw 571
San Jose 510
Jacksonville 328
Beijing 231
Nanjing 216
San Mateo 207
Dearborn 188
Houston 178
Ann Arbor 174
Dublin 174
Wilmington 166
Los Angeles 165
Hangzhou 162
Woodbridge 161
New York 128
Cambridge 122
Fairfield 120
Nürnberg 112
Chicago 104
Jakarta 101
Munich 101
Hanoi 100
Ho Chi Minh City 100
Lauterbourg 100
Seattle 97
Milan 89
Hefei 80
Nanchang 80
Lawrence 72
Bremen 71
Tokyo 67
Buffalo 66
Boston 62
Dallas 60
Cattolica 59
São Paulo 57
Frankfurt am Main 55
Hong Kong 55
Moscow 55
Redwood City 54
Kunming 50
Izmir 44
Santa Clara 39
Shanghai 39
The Dalles 39
Rome 38
Lancaster 33
Marseille 32
Shenyang 32
Tianjin 31
University Park 30
London 29
Salt Lake City 29
Auburn Hills 28
Leawood 28
Changsha 25
Helsinki 25
Jiaxing 25
Princeton 25
Hebei 23
Fremont 22
Falls Church 21
Guangzhou 21
Kent 21
Zhengzhou 21
Norwalk 20
Abidjan 19
Orem 19
Mountain View 18
Brussels 17
Da Nang 17
Baghdad 16
Chatsworth 16
Council Bluffs 16
Paris 16
Detroit 15
Elk Grove Village 15
Montreal 15
Atlanta 14
Belo Horizonte 14
Pune 14
Rio de Janeiro 14
Augusta 13
Boardman 13
Haiphong 13
Jinan 13
Lanzhou 13
Philadelphia 13
Tampa 13
Amsterdam 12
Brooklyn 12
Denver 12
Johannesburg 12
Nuremberg 12
Mexico City 11
San Francisco 11
Curitiba 10
Totale 9.124
Salva come PNG Salva come JPEG
Nome #
5-azacytidine in chronic myelomonocytic leukemia: case report and review of literature 430
Incidence of acute myeloid leukemia after breast cancer 381
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 362
Fanconi anemia gene variants in therapy-related myeloid neoplasms 322
Comparative molecular analysis of therapy-related and de novo acute promyelocytic leukemia 308
Therapy-related leukemias and myelodysplasia : susceptibility and incidence. 280
Quantification of DAPK1 Promoter Methylation in Bone Marrow and Peripheral Blood as a Follicular Lymphoma Biomarker 279
Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies 269
PTEN/PI3K/AKT PATHWAY DYSREGULATION IN MYELODYSPLASTIC GRANULOCYTES 241
GSK3β down-regulation in Mesenchymal Stem Cells from patients with Myelodysplastic Syndrome. 239
MUTATIONAL ANALYSIS OF BONE MARROW MESENCHIMAL STROMAL CELLS IN MYELOID MALIGNANCIES 236
Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database 234
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma. 233
Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin 231
CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma 230
Anemia in Diffuse Large B cell Non-Hodgkin Lymphoma: The Role of IL-6, Hepcidin and Erythropoietin 221
DEREGULATION OF PI3K/AKT SIGNALING IN BONE MARROW MESENCHIMAL STROMAL CELLS FROM PATIENTS WITH DE NOVO AND THERAPY-RELATED ACUTE MYELOID LEUKEMIA 214
Gemtuzumab ozogamicin, citosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia. 209
Defective WNT Signaling and Genetic Profile Of Endothelial Cells In Patients With Low Risk Myelodysplastic Syndromes Suggest a Contribution Of Vascular Niches To Myelodysplasia 209
Impaired bactericidal and fungicidal activities of neutrophils in patients with myelodysplastic syndrome 196
Why methylation is not a marker predictive of response to hypomethylating agents 195
Increased risk of acute myeloid leukaemia due to polymorphisms in detoxification and DNA repair enzymes. 192
Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. 192
Reduced BRCA1 expression due to promoter hypermethylation in therapy-related acute myeloid leukaemia 190
The viral load of Epstein-Barr virus (EBV) DNA in peripheral blood predicts for biological and clinical characteristics in Hodgkin lymphoma 188
MTHFR polymorphysms in myelodysplastic syndromes and therapy-related myeloid neoplasms 188
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the italian network on secondary leukemias. 188
SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. 184
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma 182
Response to 5-azacytidine in a patient with relapsed Hodgkin Lymphoma and a therapy-related myelodysplastic syndrome 181
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 180
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 180
Epigenetic changes in therapy-related MDS/AML 179
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas. 176
Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases 175
Clonal evolution in therapy-related neoplasms 173
Endothelial progenitor cell dysfunction in myelodysplastic syndromes: possible contribution of a defective vascular niche to myelodysplasia 172
Whole blood EBV-DNA predicts outcome in diffuse large B-cell lymphoma 172
Promoter methylation of DAPK1, E-cadherin and thrombospondin-1 in de novo and therapy-related myeloid neoplasms 171
Similarities and differences between therapy-related and elderly acute myeloid leukemia 170
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine 170
Polymorphism in cytokine genes as prognostic markers in Hodgkin's lymphoma 169
Polymorphisms of detoxification and DNA repair enzymes in myelodyplastic syndromes 168
Primary plasma cell leukemia followed by testicular plasmacytoma 164
An abnormal secretion of soluble mediators contributes to the hematopoietic-niche dysfunction in low-risk myelodysplastic syndrome 160
Four doses of unpegylated versus one dose of pegylated filgrastim as supportive therapy in R-CHOP-14 for elderly patients with diffuse large B-cell lymphoma 159
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma 157
Prognostic role of glutathione S-transferase polymorphisms in acute myeloid leukemia. 155
Iron in Hodgkin's lymphoma 155
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma. 155
Efficacy of a modified Stanford V regimen in patients with advanced Hodgkin's lymphoma. 154
Gene expression profiling of myelodysplastic CD34+ hematopoietic stem cells treated in vitro with decitabine. 154
PU.1 and CEBPA expression in acute myeloid leukemia. 153
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas 152
Atypical presentation of progressive multifocal leukoencephalopathy in a multiple myeloma patient after auto SCTsuccessfully treated with combination treatment. 151
Clinical significance of interleukin-10 gene polymorphisms and plasma levels in Hodgkin lymphoma. 151
The BCL2L10 Leu21Arg variant and risk of therapy-related myeloid neoplasms and de novo myelodysplastic syndromes 150
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma. 148
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 148
Anemia in diffuse large B-cell non-Hodgkin lymphoma: the role of interleukin-6, hepcidin and erythropoietin. 148
DAP-kinase hypermethylation in the bone marrow of patients with follicular lymphoma 147
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. 139
Small lymphocytic lymphoma in a patient with Fabry disease 139
Outcome of therapy-related myeloid neoplasms treated with azacitidine 137
Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes 133
Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study 131
Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia 127
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 127
Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome 127
Negative prognostic value of glutathione s-transferase (gstm1 and gstt1) deletions in adult acute myeloid leukemia. 126
Glutathione-S-transferase genotypes influence prognosis in follicular non-Hodgkin's Lymphoma 126
Deferasirox for Transfusion-Dependent Patients with Myelodysplastic Syndromes: Safety, Efficacy, and Beyond (GIMEMA MDS0306 Trial) 126
A population-based study on myelodysplastic syndromes in the Lazio Region (Italy), medical miscoding and 11-year mortality follow-up: The Gruppo Romano-Laziale Mielodisplasie experience of retrospective multicentric registry 125
The anti-leukemic effect of a novel histone deacetylase inhibitor MCT-1 and 5-aza-cytidine involves augmentation of Nur77 and inhibition of MMP-9 expression. 123
Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation 123
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a “Gruppo Romano Mielodisplasie (GROM)” multicenter study 120
Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule 119
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 118
Therapy-related myeloid neoplasms: Clinical perspectives 118
Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine 113
Myelodysplastic disorders carrying both isolated del(5q) and JAK2(V617F) mutation: concise review, with focus on lenalidomide therapy 113
Long-term efficacy and toxicity results of the FLUMIZ trial (fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in untreated follicular lymphoma) 111
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 111
Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis 109
Efficacy of combined surgery and antifungal therapies for the management of invasive zygomycoses in patients with haematological malignancies 109
Role of glutathione-S-transferase (GST) polymorphisms in patients with advanced Hodgkin lymphoma: results from the HD2000 GISL trial 106
High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study 105
Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes 103
Therapy-related myeloid neoplasms 97
Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 96
Efficacy and toxicicty of sequential high-dose therapy with peripheral blood stem cell support in patients with high-risk breast cancer 89
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ) 84
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine 84
Telomerase activity in human hematopoietic progenitor cells 82
Telomerase activity in human hematopoietic progenitor cells 81
Chronic myelomonocytic leukemia treatment with azacitidine: What have we learned so far? 80
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes 77
Genomic analysis of therapy-related acute promyelocytic leukemias arising after malignant and non-malignant disorders 76
Impairment of FOXM1 expression in mesenchymal cells from patients with myeloid neoplasms, de novo and therapy-related, may compromise their ability to support hematopoiesis 72
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile 62
Totale 16.464
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.286
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.286
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021278 0 0 0 0 0 0 0 0 0 0 247 31
2021/2022933 113 100 5 30 75 38 24 165 45 83 123 132
2022/20231.989 250 281 154 361 120 249 70 181 234 7 59 23
2023/2024835 40 259 15 20 33 148 34 34 13 24 109 106
2024/20251.956 45 61 151 60 184 32 99 73 280 135 567 269
2025/20264.555 679 123 234 386 786 337 885 350 437 331 7 0
Totale 16.564